Biotech stocks came under pressure along with the broader market in the week that ended June 12, as a worsening pandemic situation and its impact on the economy led to an across-the-board sell-off in the global markets.

The week kickstarted with the rumor of a big-ticket acquisition. AstraZeneca plc (AZN) reportedly approached Gilead Sciences, Inc. (GILD) with a bid, although experts and analysts shrugged off the possibility of a deal materializing.

The FDA promptly approved Viela Bio Inc's drug for treating neuromyelitis optica spectrum disorder.

More importantly, five biopharma companies debuted on Wall Street, raising a combined $983.25 million. The week also witnessed virtual presentations at key conferences, such as the European Hematology Association Congress. Here are the key catalysts for the unfolding week.

Conferences

• The Endocrine Society's ENDO Online 2020: June 8 - June 22.
• 25th Edition of the European Hematology Association, or EHA, Annual Congress held in virtual format: June 11 - June 21.
• American Academy of Dermatology, or AAD, Virtual Meeting Experience: June 12 - June 14.
• The American Diabetes Association, or ADA, 80th Scientific Sessions – Virtual: June 12 - June 16.
• The World Federation of Hemophilia, or WFH, Virtual Summit: June 14 - June 19.

PDUFA Dates

• The FDA is scheduled to give its verdict on Merck & Co., Inc.'s (MRK) Keytruda as a monotherapy option for unresectable or metastatic solid tumors, with tissue tumor mutational burden-high on Tuesday, June 16.
• Ultragenyx Pharmaceutical Inc. (RARE) and its Japanese partner Kyowa Kirin have a tryst with the FDA, as the agency is set to rule on hypophosphatemia treatment candidate burosumab on Thursday, June 18.
• The regulatory agency will also decide on Epizyme Inc. (EPZM)'s regulatory application for label expansion for tazemetostat, this time for follicular lymphoma on the same date.
• Nabriva Therapeutics PLC – ADR (NBRV) is knocking at the FDA altar for the second time on Friday, June 19, for its investigational antibiotic contepo for treating complicated urinary tract infection. Late May, the company hinted at the decision being delayed due to the FDA requiring to inspect facilities of third-party manufacturers in Europe.
• Evoke Pharma Inc. (EVOK) has a PDUFA date set for Friday, June 19, for its Gimoti to treat women with acute and recurrent diabetic gastroparesis.

Adcom Meetings

FDA's Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee will consider, through teleconferencing, SP 2577, as presented by Salarius Pharmaceuticals Inc., as well as marizomib, as presented by Celgene (CELG), a subsidiary of Bristol-Myers Squibb Co. (BMY). SP 2577 is being evaluated for the treatment of relapsed/refractory patients with Ewing sarcoma, and marizomib for multiple myeloma.

The FDA said the subcommittee will consider and discuss issues relating to the development of each product for pediatric use and provide guidance to facilitate the formulation of written requests for pediatric studies, if appropriate.

Clinical Readouts/Presentations

ProQR Therapeutics N.V. (PRQR) will make a virtual presentation of data from the Phase 1/2 trial of intravitreal sepofarsen, an antisense oligonucleotide, in Leber congenital amaurosis 10 due to p.Cys998X mutation in the CEP290 gene. The data is to be shared via a video presentation through the Association for Research in Vision and Ophthalmology, and will be available online on Monday, June 15.

Sanofi SA (SNY) is scheduled to host a virtual scientific session on Tuesday, June 16, to present data from the Phase 3 COMET trial of investigational enzyme replacement therapy avalglucosidase alfa in patients with late-onset Pompe disease.

Catalyst Biosciences Inc. (CBIO) is due to present at the WFH virtual summit Phase 2a data for factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in hemophilia B.

Earnings

• Centogene NV (CNTG) is expecting earnings on Monday, June 15, before the market open.
• BioNano Genomics Inc. is expecting earnings on Thursday, June 18, after the market close.
• Urovant Sciences Ltd. (UROV) is expecting earnings on Thursday, June 18, after the market close.

IPOs

Royalty Pharma (RPRX), which buys royalties for late-stage and commercial drugs, has filed to offer 70 million shares in an initial public offering at an estimated price range of $25-$28. The company has applied for listing its shares on the Nasdaq under the ticker symbol RPRX.